Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.

"Disclosure statement R. Yarchoan reports receiving drug supply for laboratory research from Janssen Pharmaceuticals and CTI BioPharma. R. Yarchoan, K. Lurain, and R. Ramaswami report receiving research support from Celgene (now Bristol Myers Squibb) through CRADAs with the NCI and receiving drugs for clinical trials from Merck, EMD-Serono, Eli Lilly, and Janssen through CRADAs with the NCI. R. Yarchoan is a co-inventor on US Patent 10,001,483 entitled “Methods for the treatment of Kaposi’s sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers.” An immediate family member of R. Yarchoan is a co-inventor on patents or patent applications related to internalization of target receptors, epigenetic analysis, and ephrin tyrosine kinase inhibitors. All rights, title, and interest to these patents have been assigned to the U.S. Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). No potential conflicts of interest were disclosed by the other authors."

"This study was supported by the intramural research program of the NCI, NIH. Some of the Dara used in this study was provided by Janssen Pharmaceuticals under a CRADA with the NCI. We would like to thank our patients and their families who contributed to this research."